The University of Chicago Header Logo

Connection

Olufunmilayo Olopade to Adult

This is a "connection" page, showing publications Olufunmilayo Olopade has written about Adult.
Connection Strength

2.349
  1. Oncology Training Needs Assessment Among Health Care Professionals in Nigeria. JCO Glob Oncol. 2022 05; 8:e2200017.
    View in: PubMed
    Score: 0.054
  2. Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. Nat Commun. 2021 11 26; 12(1):6946.
    View in: PubMed
    Score: 0.053
  3. Traditional medicine usage among adult women in Ibadan, Nigeria: a cross-sectional study. BMC Complement Med Ther. 2020 Mar 20; 20(1):93.
    View in: PubMed
    Score: 0.047
  4. Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk. Fam Cancer. 2018 10; 17(4):495-505.
    View in: PubMed
    Score: 0.042
  5. Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers. Clin Cancer Res. 2019 03 15; 25(6):1786-1794.
    View in: PubMed
    Score: 0.042
  6. Inherited Breast Cancer in Nigerian Women. J Clin Oncol. 2018 10 01; 36(28):2820-2825.
    View in: PubMed
    Score: 0.042
  7. Knowledge of Genetic Counseling Among Patients With Breast Cancer and Their Relatives at a Nigerian Teaching Hospital. J Glob Oncol. 2018 07; 4:1-8.
    View in: PubMed
    Score: 0.041
  8. Cancer Susceptibility Genetic Testing in a High-Risk Cohort of Urban Ashkenazi Jewish Individuals. J Genet Couns. 2018 12; 27(6):1405-1410.
    View in: PubMed
    Score: 0.041
  9. Breast Cancer Genetics Knowledge and Testing Intentions among Nigerian Professional Women. J Genet Couns. 2018 08; 27(4):863-873.
    View in: PubMed
    Score: 0.040
  10. Identification of a circulating microRNA signature to distinguish recurrence in breast cancer patients. Oncotarget. 2016 08 23; 7(34):55231-55248.
    View in: PubMed
    Score: 0.036
  11. Breast cancer risk after full-term pregnancies among African women from Nigeria, Cameroon, and Uganda. Cancer. 2015 Jul 01; 121(13):2237-43.
    View in: PubMed
    Score: 0.033
  12. Social barriers to diagnosis and treatment of breast cancer in patients presenting at a teaching hospital in Ibadan, Nigeria. Glob Public Health. 2015; 10(3):331-44.
    View in: PubMed
    Score: 0.032
  13. Inherited predisposition to breast cancer among African American women. Breast Cancer Res Treat. 2015 Jan; 149(1):31-9.
    View in: PubMed
    Score: 0.032
  14. Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report. Clin Breast Cancer. 2015 Apr; 15(2):e155-8.
    View in: PubMed
    Score: 0.032
  15. Tumor genome analysis includes germline genome: are we ready for surprises? Int J Cancer. 2015 Apr 01; 136(7):1559-67.
    View in: PubMed
    Score: 0.032
  16. Neo-adjuvant capecitabine chemotherapy in women with newly diagnosed locally advanced breast cancer in a resource-poor setting (Nigeria): efficacy and safety in a phase II feasibility study. Breast J. 2013 Sep-Oct; 19(5):470-7.
    View in: PubMed
    Score: 0.029
  17. Expression and sub-cellular localization of an epigenetic regulator, co-activator arginine methyltransferase 1 (CARM1), is associated with specific breast cancer subtypes and ethnicity. Mol Cancer. 2013 May 10; 12(1):40.
    View in: PubMed
    Score: 0.029
  18. Level of awareness of mammography among women attending outpatient clinics in a teaching hospital in Ibadan, South-West Nigeria. BMC Public Health. 2013 Jan 16; 13:40.
    View in: PubMed
    Score: 0.028
  19. Resistance to trastuzumab in HER2-positive mucinous invasive ductal breast carcinoma. Clin Breast Cancer. 2013 Apr; 13(2):156-8.
    View in: PubMed
    Score: 0.028
  20. Microsatellites in the estrogen receptor (ESR1, ESR2) and androgen receptor (AR) genes and breast cancer risk in African American and Nigerian women. PLoS One. 2012; 7(7):e40494.
    View in: PubMed
    Score: 0.027
  21. Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry. Breast Cancer Res Treat. 2012 Jul; 134(2):889-94.
    View in: PubMed
    Score: 0.027
  22. Body fat distribution and breast cancer risk: findings from the Nigerian breast cancer study. Cancer Causes Control. 2012 Apr; 23(4):565-74.
    View in: PubMed
    Score: 0.027
  23. Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis. 2012 Apr; 33(4):835-40.
    View in: PubMed
    Score: 0.027
  24. Novel germline PALB2 truncating mutations in African American breast cancer patients. Cancer. 2012 Mar 01; 118(5):1362-70.
    View in: PubMed
    Score: 0.026
  25. Case-control study of body size and breast cancer risk in Nigerian women. Am J Epidemiol. 2010 Sep 15; 172(6):682-90.
    View in: PubMed
    Score: 0.024
  26. Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer. Breast Cancer Res Treat. 2010 Dec; 124(3):857-61.
    View in: PubMed
    Score: 0.024
  27. Searching for large genomic rearrangements of the BRCA1 gene in a Nigerian population. Breast Cancer Res Treat. 2010 Nov; 124(2):573-7.
    View in: PubMed
    Score: 0.024
  28. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009 Sep 20; 27(27):4515-21.
    View in: PubMed
    Score: 0.022
  29. Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States. J Clin Oncol. 2009 Mar 10; 27(8):1184-90.
    View in: PubMed
    Score: 0.022
  30. Evidence for an ancient BRCA1 mutation in breast cancer patients of Yoruban ancestry. Fam Cancer. 2009; 8(1):15-22.
    View in: PubMed
    Score: 0.021
  31. Family history of pancreatic cancer in a high-risk cancer clinic: implications for risk assessment. J Genet Couns. 2008 Aug; 17(4):365-72.
    View in: PubMed
    Score: 0.021
  32. Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet Med. 2008 Mar; 10(3):161-166.
    View in: PubMed
    Score: 0.020
  33. Parity and breastfeeding are protective against breast cancer in Nigerian women. Br J Cancer. 2008 Mar 11; 98(5):992-6.
    View in: PubMed
    Score: 0.020
  34. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and breast cancer risk in Africans. Breast Cancer Res Treat. 2008 Jul; 110(2):367-76.
    View in: PubMed
    Score: 0.020
  35. UDP-Glucuronosyltransferase 1A1 gene polymorphisms and total bilirubin levels in an ethnically diverse cohort of women. Drug Metab Dispos. 2007 Aug; 35(8):1254-61.
    View in: PubMed
    Score: 0.019
  36. Correlates of depressive symptoms among women seeking cancer genetic counseling and risk assessment at a high-risk cancer clinic. J Genet Couns. 2006 Aug; 15(4):267-76.
    View in: PubMed
    Score: 0.018
  37. BRCA2 mutation and the risk of hematologic malignancy. Leuk Lymphoma. 2006 Apr; 47(4):765-7.
    View in: PubMed
    Score: 0.018
  38. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA. 2005 Oct 19; 294(15):1925-33.
    View in: PubMed
    Score: 0.017
  39. Racial and ethnic disparities in breast cancer: a multilevel perspective. Med Clin North Am. 2005 Jul; 89(4):753-70.
    View in: PubMed
    Score: 0.017
  40. Complete allelic analysis of BRCA1 and BRCA2 variants in young Nigerian breast cancer patients. J Med Genet. 2005 Mar; 42(3):276-81.
    View in: PubMed
    Score: 0.016
  41. Breast cancer and race: a rising tide does not lift all boats equally. Perspect Biol Med. 2005; 48(1 Suppl):S166-75.
    View in: PubMed
    Score: 0.016
  42. Benign breast disease and breast cancer risk in African women: a case-control study. Cancer Causes Control. 2024 May; 35(5):787-798.
    View in: PubMed
    Score: 0.015
  43. Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a BRCA1 or BRCA2 Mutation. Cancer Res Commun. 2023 11 28; 3(11):2420-2429.
    View in: PubMed
    Score: 0.015
  44. Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial: A Randomized Clinical Trial. JAMA Oncol. 2023 Nov 01; 9(11):1547-1555.
    View in: PubMed
    Score: 0.015
  45. Obesity and height in urban Nigerian women with breast cancer. Ann Epidemiol. 2003 Jul; 13(6):455-61.
    View in: PubMed
    Score: 0.015
  46. Response to Treatment, Racial and Ethnic Disparity, and Survival in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy in the US. JAMA Netw Open. 2023 03 01; 6(3):e235834.
    View in: PubMed
    Score: 0.014
  47. Validation of the Nigerian Breast Cancer Study Model for Predicting Individual Breast Cancer Risk in Cameroon and Uganda. Cancer Epidemiol Biomarkers Prev. 2023 01 09; 32(1):98-104.
    View in: PubMed
    Score: 0.014
  48. Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal. Cancer Epidemiol Biomarkers Prev. 2022 07 01; 31(7):1351-1358.
    View in: PubMed
    Score: 0.014
  49. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res. 2002 Mar 01; 62(5):1481-8.
    View in: PubMed
    Score: 0.013
  50. Associations between age of menarche and genetic variation in women of African descent: genome-wide association study and polygenic score analysis. J Epidemiol Community Health. 2022 04; 76(4):411-417.
    View in: PubMed
    Score: 0.013
  51. Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiol Biomarkers Prev. 2021 11; 30(11):2038-2043.
    View in: PubMed
    Score: 0.013
  52. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet. 2001 Mar; 38(3):159-64.
    View in: PubMed
    Score: 0.012
  53. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat Commun. 2021 02 17; 12(1):1078.
    View in: PubMed
    Score: 0.012
  54. Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients. Breast Cancer Res. 2021 02 04; 23(1):18.
    View in: PubMed
    Score: 0.012
  55. Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol. 2020 12; 159(3):820-826.
    View in: PubMed
    Score: 0.012
  56. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 09 01; 6(9):1355-1362.
    View in: PubMed
    Score: 0.012
  57. Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. Hum Genet. 2000 Aug; 107(2):186-91.
    View in: PubMed
    Score: 0.012
  58. Protein truncating BRCA1 and BRCA2 mutations in African women with pre-menopausal breast cancer. Hum Genet. 2000 Aug; 107(2):192-4.
    View in: PubMed
    Score: 0.012
  59. Susceptibility gene for familial acute myeloid leukemia associated with loss of 5q and/or 7q is not localized on the commonly deleted portion of 5q. Genes Chromosomes Cancer. 2000 Jun; 28(2):164-72.
    View in: PubMed
    Score: 0.012
  60. Longitudinal follow-up after telephone disclosure in the randomized COGENT study. Genet Med. 2020 08; 22(8):1401-1406.
    View in: PubMed
    Score: 0.012
  61. Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
    View in: PubMed
    Score: 0.012
  62. Care Coordination for Breast Cancer Survivors in Urban Underserved Communities: Will Treatment Summaries and Survivorship Care Plans Be Enough? J Racial Ethn Health Disparities. 2020 06; 7(3):577-583.
    View in: PubMed
    Score: 0.012
  63. Prevalence of Inherited Mutations in Breast Cancer Predisposition Genes among Women in Uganda and Cameroon. Cancer Epidemiol Biomarkers Prev. 2020 02; 29(2):359-367.
    View in: PubMed
    Score: 0.011
  64. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. J Clin Oncol. 2020 03 01; 38(7):674-685.
    View in: PubMed
    Score: 0.011
  65. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Res. 2020 02 01; 80(3):624-638.
    View in: PubMed
    Score: 0.011
  66. Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study. Cancer Med. 2019 09; 8(12):5609-5618.
    View in: PubMed
    Score: 0.011
  67. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2019 07; 121(2):180-192.
    View in: PubMed
    Score: 0.011
  68. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. J Natl Cancer Inst. 2019 04 01; 111(4):350-364.
    View in: PubMed
    Score: 0.011
  69. Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2019 Jun; 175(2):443-449.
    View in: PubMed
    Score: 0.011
  70. Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. Br J Cancer. 2019 02; 120(4):398-403.
    View in: PubMed
    Score: 0.011
  71. Implementation of a Novel Medical School Multidisciplinary and Interprofessional Oncology Curriculum: a Mixed Method Study. J Cancer Educ. 2019 02; 34(1):50-55.
    View in: PubMed
    Score: 0.011
  72. Identification of novel common breast cancer risk variants at the 6q25 locusĀ among Latinas. Breast Cancer Res. 2019 01 14; 21(1):3.
    View in: PubMed
    Score: 0.011
  73. Preferences for in-person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study. Clin Genet. 2019 02; 95(2):293-301.
    View in: PubMed
    Score: 0.011
  74. Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy? Cancer. 2019 01 15; 125(2):213-222.
    View in: PubMed
    Score: 0.011
  75. A longitudinal study of the prevalence and characteristics of breast disorders detected by clinical breast examination during pregnancy and six months postpartum in Ibadan, Southwestern Nigeria. BMC Womens Health. 2018 09 19; 18(1):152.
    View in: PubMed
    Score: 0.011
  76. Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results. J Natl Cancer Inst. 2018 09 01; 110(9):985-993.
    View in: PubMed
    Score: 0.010
  77. Predisposition testing for inherited breast cancer. Oncology (Williston Park). 1998 Aug; 12(8):1227-41; discussion 1241-2.
    View in: PubMed
    Score: 0.010
  78. CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Cancer Epidemiol Biomarkers Prev. 2018 11; 27(11):1364-1370.
    View in: PubMed
    Score: 0.010
  79. Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma. Genes Chromosomes Cancer. 1998 May; 22(1):72-8.
    View in: PubMed
    Score: 0.010
  80. Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2018 Jun; 169(3):561-571.
    View in: PubMed
    Score: 0.010
  81. Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst. 2018 02 01; 110(2).
    View in: PubMed
    Score: 0.010
  82. Genetic variants demonstrating flip-flop phenomenon and breast cancer risk prediction among women of African ancestry. Breast Cancer Res Treat. 2018 Apr; 168(3):703-712.
    View in: PubMed
    Score: 0.010
  83. Household air pollution and chronic hypoxia in the placenta of pregnant Nigerian women: A randomized controlled ethanol Cookstove intervention. Sci Total Environ. 2018 Apr 01; 619-620:212-220.
    View in: PubMed
    Score: 0.010
  84. Genetic variation in the vitamin D related pathway and breast cancer risk in women of African ancestry in the root consortium. Int J Cancer. 2018 01 01; 142(1):36-43.
    View in: PubMed
    Score: 0.010
  85. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci Am. 1997 Jul-Aug; 3(4):230-7.
    View in: PubMed
    Score: 0.010
  86. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2017 07 01; 109(7).
    View in: PubMed
    Score: 0.010
  87. Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
    View in: PubMed
    Score: 0.010
  88. Recurrent germ-line BRCA1 mutations in extended African American families with early-onset breast cancer. Am J Hum Genet. 1997 May; 60(5):1233-6.
    View in: PubMed
    Score: 0.010
  89. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J Clin Oncol. 2017 Jul 10; 35(20):2240-2250.
    View in: PubMed
    Score: 0.010
  90. Fast bilateral breast coverage with high spectral and spatial resolution (HiSS) MRI at 3T. J Magn Reson Imaging. 2017 11; 46(5):1341-1348.
    View in: PubMed
    Score: 0.009
  91. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34.
    View in: PubMed
    Score: 0.009
  92. Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry. Hum Genet. 2016 10; 135(10):1145-59.
    View in: PubMed
    Score: 0.009
  93. Familial myeloid leukemia associated with loss of the long arm of chromosome 5. Leukemia. 1996 Apr; 10(4):669-74.
    View in: PubMed
    Score: 0.009
  94. An Evaluation of Psychosocial and Religious Belief Differences in a Diverse Racial and Socioeconomic Urban Cancer Population. J Racial Ethn Health Disparities. 2017 04; 4(2):140-148.
    View in: PubMed
    Score: 0.009
  95. Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect. Cancer. 2016 06 15; 122(12):1913-20.
    View in: PubMed
    Score: 0.009
  96. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2016 Feb 09; 18(1):15.
    View in: PubMed
    Score: 0.009
  97. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer. 2016 Jan 15; 122(2):304-11.
    View in: PubMed
    Score: 0.009
  98. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst. 2016 Feb; 108(2).
    View in: PubMed
    Score: 0.009
  99. Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies. Blood. 1995 Sep 01; 86(5):1931-8.
    View in: PubMed
    Score: 0.009
  100. Mutation spectrum and risk of colorectal cancer in African American families with Lynch syndrome. Gastroenterology. 2015 Nov; 149(6):1446-53.
    View in: PubMed
    Score: 0.008
  101. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. JAMA Oncol. 2015 Jun; 1(3):306-13.
    View in: PubMed
    Score: 0.008
  102. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015 Apr 07; 313(13):1347-61.
    View in: PubMed
    Score: 0.008
  103. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet. 2015 Feb; 47(2):164-71.
    View in: PubMed
    Score: 0.008
  104. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2014 Dec 31; 16(6):3416.
    View in: PubMed
    Score: 0.008
  105. Metformin for primary colorectal cancer prevention in patients with diabetes: a case-control study in a US population. Cancer. 2015 Apr 01; 121(7):1071-8.
    View in: PubMed
    Score: 0.008
  106. National survey of US oncologists' knowledge, attitudes, and practice patterns regarding herb and supplement use by patients with cancer. J Clin Oncol. 2014 Dec 20; 32(36):4095-101.
    View in: PubMed
    Score: 0.008
  107. Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):308-16.
    View in: PubMed
    Score: 0.008
  108. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014 Nov; 148(2):397-406.
    View in: PubMed
    Score: 0.008
  109. Relationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional study. Breast Cancer Res. 2014; 16(4):424.
    View in: PubMed
    Score: 0.008
  110. Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014 Jul; 146(2):421-7.
    View in: PubMed
    Score: 0.008
  111. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet. 2014 04; 10(4):e1004256.
    View in: PubMed
    Score: 0.008
  112. Breast cancer detected on an incident (second or subsequent) round of screening MRI: MRI features of false-negative cases. AJR Am J Roentgenol. 2013 Nov; 201(5):1155-63.
    View in: PubMed
    Score: 0.008
  113. Risk factors for pregnancy-associated breast cancer: a report from the Nigerian Breast Cancer Study. Ann Epidemiol. 2013 Sep; 23(9):551-7.
    View in: PubMed
    Score: 0.007
  114. MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency. Tumour Biol. 2013 Dec; 34(6):3945-58.
    View in: PubMed
    Score: 0.007
  115. A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat. 2013 May; 139(1):145-53.
    View in: PubMed
    Score: 0.007
  116. Relationship between household air pollution from biomass smoke exposure, and pulmonary dysfunction, oxidant-antioxidant imbalance and systemic inflammation in rural women and children in Nigeria. Glob J Health Sci. 2013 Mar 18; 5(4):28-38.
    View in: PubMed
    Score: 0.007
  117. Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers. Carcinogenesis. 2013 Jul; 34(7):1520-8.
    View in: PubMed
    Score: 0.007
  118. Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? Breast Cancer Res Treat. 2013 Feb; 138(1):273-9.
    View in: PubMed
    Score: 0.007
  119. Clinical, morphologic, and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia. Blood. 1992 Dec 01; 80(11):2873-82.
    View in: PubMed
    Score: 0.007
  120. Classification of breast lesions pre-contrast injection using water resonance lineshape analysis. NMR Biomed. 2013 May; 26(5):569-77.
    View in: PubMed
    Score: 0.007
  121. Computerized analysis of mammographic parenchymal patterns on a large clinical dataset of full-field digital mammograms: robustness study with two high-risk datasets. J Digit Imaging. 2012 Oct; 25(5):591-8.
    View in: PubMed
    Score: 0.007
  122. A genome-wide association study of breast cancer in women of African ancestry. Hum Genet. 2013 Jan; 132(1):39-48.
    View in: PubMed
    Score: 0.007
  123. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol. 2012 Apr 20; 30(12):1321-8.
    View in: PubMed
    Score: 0.007
  124. Genetic susceptibility to type 2 diabetes and breast cancer risk in women of European and African ancestry. Cancer Epidemiol Biomarkers Prev. 2012 Mar; 21(3):552-6.
    View in: PubMed
    Score: 0.007
  125. When parents disclose BRCA1/2 test results: their communication and perceptions of offspring response. Cancer. 2012 Jul 01; 118(13):3417-25.
    View in: PubMed
    Score: 0.007
  126. DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy. Mol Carcinog. 2012 Oct; 51 Suppl 1:E83-93.
    View in: PubMed
    Score: 0.007
  127. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012 Apr; 132(3):1049-62.
    View in: PubMed
    Score: 0.007
  128. Lack of association between common single nucleotide polymorphisms in the TERT-CLPTM1L locus and breast cancer in women of African ancestry. Breast Cancer Res Treat. 2012 Feb; 132(1):341-5.
    View in: PubMed
    Score: 0.007
  129. Clinicopathological significance and prognostic value of Xeroderma pigmentosum complementary group C (XPC) expression in sporadic breast cancer patients. Med Oncol. 2012 Sep; 29(3):1543-53.
    View in: PubMed
    Score: 0.007
  130. Clinical significance of KISS1 protein expression for brain invasion and metastasis. Cancer. 2012 Apr 15; 118(8):2096-105.
    View in: PubMed
    Score: 0.006
  131. Atopy is associated with asthma in adults living in rural and urban southwestern Nigeria. J Asthma. 2011 Nov; 48(9):894-900.
    View in: PubMed
    Score: 0.006
  132. Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Res. 2011 Sep 01; 71(17):5792-805.
    View in: PubMed
    Score: 0.006
  133. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer. 2012 Feb 15; 118(4):908-13.
    View in: PubMed
    Score: 0.006
  134. Performance of Lynch syndrome predictive models in a multi-center US referral population. Am J Gastroenterol. 2011 Oct; 106(10):1822-7; quiz 1828.
    View in: PubMed
    Score: 0.006
  135. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011 Apr 26; 104(9):1384-92.
    View in: PubMed
    Score: 0.006
  136. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2011 May; 127(1):287-96.
    View in: PubMed
    Score: 0.006
  137. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 2010 Dec 01; 70(23):9742-54.
    View in: PubMed
    Score: 0.006
  138. Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. J Med Genet. 2011 Jan; 48(1):64-8.
    View in: PubMed
    Score: 0.006
  139. Characterizing early contrast uptake of ductal carcinoma in situ with high temporal resolution dynamic contrast-enhanced MRI of the breast: a pilot study. Phys Med Biol. 2010 Oct 07; 55(19):N473-85.
    View in: PubMed
    Score: 0.006
  140. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat. 2011 Aug; 128(3):703-711.
    View in: PubMed
    Score: 0.006
  141. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010 Sep 01; 304(9):967-75.
    View in: PubMed
    Score: 0.006
  142. Parent opinions regarding the genetic testing of minors for BRCA1/2. J Clin Oncol. 2010 Jul 20; 28(21):3498-505.
    View in: PubMed
    Score: 0.006
  143. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol. 2010 Jun; 176(6):2911-20.
    View in: PubMed
    Score: 0.006
  144. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat. 2010 Nov; 124(1):195-203.
    View in: PubMed
    Score: 0.006
  145. Long-term survival of patients with intermediate and high grade lymphoma treated with COMLA/ABP. Leukemia. 1990 Feb; 4(2):127-31.
    View in: PubMed
    Score: 0.006
  146. Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Cancer Res. 2009 Jul 15; 69(14):5801-10.
    View in: PubMed
    Score: 0.006
  147. Learning of your parent's BRCA mutation during adolescence or early adulthood: a study of offspring experiences. Psychooncology. 2009 Feb; 18(2):200-8.
    View in: PubMed
    Score: 0.005
  148. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
    View in: PubMed
    Score: 0.005
  149. Glucocorticoid receptor expression in breast cancer associates with older patient age. Breast Cancer Res Treat. 2009 Aug; 116(3):441-7.
    View in: PubMed
    Score: 0.005
  150. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer. 2008 Jul 22; 99(2):371-4.
    View in: PubMed
    Score: 0.005
  151. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet. 2008 Jun; 40(6):703-6.
    View in: PubMed
    Score: 0.005
  152. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet. 2008 Apr; 82(4):937-48.
    View in: PubMed
    Score: 0.005
  153. Should genetic testing for BRCA1/2 be permitted for minors? Opinions of BRCA mutation carriers and their adult offspring. Am J Med Genet C Semin Med Genet. 2008 Feb 15; 148C(1):70-7.
    View in: PubMed
    Score: 0.005
  154. Genetic variation in IGFBP2 and IGFBP5 is associated with breast cancer in populations of African descent. Hum Genet. 2008 Apr; 123(3):247-55.
    View in: PubMed
    Score: 0.005
  155. RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. Cancer Res. 2008 Jan 01; 68(1):22-5.
    View in: PubMed
    Score: 0.005
  156. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer. 2007 Dec 15; 121(12):2661-7.
    View in: PubMed
    Score: 0.005
  157. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008 Jan; 108(1):3-9.
    View in: PubMed
    Score: 0.005
  158. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet. 2007 Dec; 81(6):1186-200.
    View in: PubMed
    Score: 0.005
  159. How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults. J Clin Oncol. 2007 Aug 20; 25(24):3705-11.
    View in: PubMed
    Score: 0.005
  160. AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev. 2007 Jul; 16(7):1416-21.
    View in: PubMed
    Score: 0.005
  161. Fractal analysis of mammographic parenchymal patterns in breast cancer risk assessment. Acad Radiol. 2007 May; 14(5):513-21.
    View in: PubMed
    Score: 0.005
  162. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med. 2006 Dec; 3(12):e486.
    View in: PubMed
    Score: 0.005
  163. The I1307K APC polymorphism in Ashkenazi Jews with colorectal cancer: clinical and pathologic features. Cancer Genet Cytogenet. 2006 Aug; 169(1):33-8.
    View in: PubMed
    Score: 0.005
  164. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006 Jul 12; 296(2):185-92.
    View in: PubMed
    Score: 0.005
  165. "Why take it if you don't have anything?" breast cancer risk perceptions and prevention choices at a public hospital. J Gen Intern Med. 2006 Jul; 21(7):779-85.
    View in: PubMed
    Score: 0.005
  166. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006 May 01; 118(9):2281-4.
    View in: PubMed
    Score: 0.004
  167. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006 Jun 01; 24(16):2437-43.
    View in: PubMed
    Score: 0.004
  168. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol. 2006 Mar; 7(3):223-9.
    View in: PubMed
    Score: 0.004
  169. High spectral and spatial resolution MRI of breast lesions: preliminary clinical experience. AJR Am J Roentgenol. 2006 Jan; 186(1):30-7.
    View in: PubMed
    Score: 0.004
  170. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer. 2005 Dec 20; 117(6):988-91.
    View in: PubMed
    Score: 0.004
  171. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005 Nov 01; 23(31):7804-10.
    View in: PubMed
    Score: 0.004
  172. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control. 2005 Aug; 16(6):667-74.
    View in: PubMed
    Score: 0.004
  173. Computerized texture analysis of mammographic parenchymal patterns of digitized mammograms. Acad Radiol. 2005 Jul; 12(7):863-73.
    View in: PubMed
    Score: 0.004
  174. A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev. 2005 Jun; 14(6):1534-8.
    View in: PubMed
    Score: 0.004
  175. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005 Jan; 96(1):222-6.
    View in: PubMed
    Score: 0.004
  176. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004 Jun 15; 22(12):2328-35.
    View in: PubMed
    Score: 0.004
  177. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res. 2004 Mar 15; 10(6):2029-34.
    View in: PubMed
    Score: 0.004
  178. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004 Mar 15; 22(6):1055-62.
    View in: PubMed
    Score: 0.004
  179. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res. 2004 Jan 15; 10(2):499-507.
    View in: PubMed
    Score: 0.004
  180. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2002 Dec 04; 94(23):1773-9.
    View in: PubMed
    Score: 0.004
  181. Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers. Radiology. 2002 Nov; 225(2):519-26.
    View in: PubMed
    Score: 0.004
  182. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002 May 23; 346(21):1616-22.
    View in: PubMed
    Score: 0.003
  183. Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope. 2002 Mar; 112(3):472-81.
    View in: PubMed
    Score: 0.003
  184. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics. 2001 Oct; 11(7):635-8.
    View in: PubMed
    Score: 0.003
  185. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol. 2000 Oct 01; 18(19):3360-9.
    View in: PubMed
    Score: 0.003
  186. Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression. Clin Cancer Res. 2000 Oct; 6(10):4043-8.
    View in: PubMed
    Score: 0.003
  187. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet. 1999 Nov 27; 354(9193):1846-50.
    View in: PubMed
    Score: 0.003
  188. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998 Jul; 16(7):2417-25.
    View in: PubMed
    Score: 0.003
  189. CDKN2 gene deletion is not found in chronic lymphoid leukaemias of B- and T-cell origin but is frequent in acute lymphoblastic leukaemia. Br J Haematol. 1995 Dec; 91(4):865-70.
    View in: PubMed
    Score: 0.002
  190. Methylthioadenosine phosphorylase deficiency in human non-small cell lung cancers. Cancer Res. 1993 Mar 01; 53(5):1098-101.
    View in: PubMed
    Score: 0.002
  191. Correlation of cytogenetic analysis and loss of heterozygosity studies in human diffuse astrocytomas and mixed oligo-astrocytomas. Genes Chromosomes Cancer. 1992 Nov; 5(4):357-74.
    View in: PubMed
    Score: 0.002
  192. Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11). Genes Chromosomes Cancer. 1990 Jul; 2(2):147-58.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.